CHHiP
Disease site: Urological
Treatment Modality: Radiotherapy
Status: In active follow-up
Patients are randomised between conventional radiotherapy fractionation using a total dose of 74Gy in 37 fractions over 7.4 weeks using conformal and intensity modulated radiotherapy techniques and the experimental groups of 57Gy in 19 fractions over 3.8 weeks and 60Gy in 20 fractions over 4 weeks.
The main aim is to test the hypothesis that hypofractionated radiotherapy schedules for localised prostate cancer will improve the therapeutic ratio by either:
• Improving tumour control
• Reducing normal tissue side effects
The trial aims to recruit over 2100 patients.
Chief Investigator: Professor David Dearnaley, Royal Marsden Hospital, Sutton
Sponsor: Institute of Cancer Research
Source of UK funding: Cancer Research UK.
ISRCTN: 97182923.
In the Clinical Trials Section
